PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma Company focused on developing and commercializing innovative gene ...

Ever since the first CAR-T launches several years ago, lengthy manufacturing timelines have been one drawback of this promising drug class. But with a new FDA blessing, Gilead Sciences is expediting ...

Next-gen benchtop system enables engineers to move from Gerber file to fully assembled, production-grade circuit boards within a single integrated platform Expected to become commercially available ...

While USAR has been seen as pre-revenue, buried in analyst snapshots is a $38.4 million revenue estimate for FY2025, suggesting commercial production or contracted offtake is closer than assumed.

PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene ...

(MENAFN- EIN Presswire) EINPresswire/ -- Electroninks, the leader in metal complex inks for additive manufacturing and advanced semiconductor packaging, today announced the commercial launch timeline ...